Vir Biotechnology (NASDAQ:VIR) Price Target Cut to $22.00

Vir Biotechnology (NASDAQ:VIR – Free Report) had its price target cut by Needham & Company LLC from $32.00 to $22.00 in a research note released on Thursday morning, Benzinga reports. The firm currently has a buy rating on the stock. Several other brokerages have also commented on VIR. SVB Securities dropped their price target on […]

Related Keywords

Canada ,Alaska ,United States ,China ,Saira Ramasastry ,Endurance Cayman Ltd Svf ,Summerhaven Investment Management ,Alaska Department Of Revenue ,Needham Company ,Royal Bank ,Vir Biotechnology Inc ,China Universal Asset Management Co ,Commonwealth Equity Services ,Vir Biotechnology Company Profile ,Morgan Stanley ,Securities Exchange Commission ,Vir Biotechnology ,Free Report ,Moderate Buy ,Get Free Report ,Director Saira Ramasastry ,Exchange Commission ,Ltd Svf ,Haven Investment Management ,Universal Asset Management ,Alaska Department ,Equity Services ,Vir Biotechnology Daily ,Nasdaq Vir ,Ivir ,Medical ,Lower Price Target ,Needham Company Llc ,